Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
14.05(c) 15.2(c) 15.8(c) 16.1(c) 15.9(c) Last
505 925 1 024 058 1 038 734 706 665 1 296 644 Volume
+2.18% +8.19% +3.95% +1.90% -1.24% Change
More quotes
Financials ($)
Sales 2017 168 M
EBIT 2017 -24,9 M
Net income 2017 -21,0 M
Debt 2017 -
Yield 2017 -
Sales 2018 202 M
EBIT 2018 -5,44 M
Net income 2018 -5,22 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 4,22x
Capi. / Sales2018 3,51x
Capitalization 708 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes HETLIOZ,... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
06/15 VANDA PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders..
06/15 VANDA PHARMACEUTICALS : Announces Participation at June 2017 Investor Conference..
06/05 VANDA PHARMACEUTICALS : Announces Participation at June 2017 Investor Conference..
05/30 VANDA PHARMACEUTICALS : Research Reports Initiation on Biotech Stocks -- Corcept..
05/11 VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 42nd Annual Health Care ..
05/03 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
05/03 VANDA PHARMACEUTICALS : reports 1Q loss
05/02 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
05/02 VANDA PHARMACEUTICALS : Reports First Quarter 2017 Financial Results
05/01 VANDA PHARMACEUTICALS : to Present at the Deutsche Bank 42nd Annual Health Care ..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/21Vanda Pharmaceuticals Inc. $VNDA Position Held by Palo Alto Investors LLC  
06/19BRIEF-Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceut.. 
06/19Vanda Pharmaceuticals $VNDA Earning Positive Media Coverage, Report Shows  
06/16Vanda Pharmaceuticals Inc. $VNDA Stake Increased by Prudential Financial Inc... 
06/14Vanda Pharmaceuticals upgraded by Zacks Investment Research to hold.  
More tweets
Qtime:14
News from SeekingAlpha
06/21 Vanda Pharmaceuticals (VNDA) Presents At JMP Securities Life Sciences Confere..
06/21 VANDA : Several Catalysts Coming Up
06/07 Vanda Pharmaceuticals (VNDA) Presents At Jefferies 2017 Global Healthcare Con..
05/26 Premarket analyst action - healthcare
05/10 Commentary On Great Point Partners' Positions Part 1
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 21,3 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-0.31%708
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..40.93%54 987
VERTEX PHARMACEUTICALS81.21%33 251
More Results